Before joining Opsona in Feb 2012, Martin was the Managing Director and Co-founder of Affitech A/S, a biopharmaceutical company focused on the discovery and development of human antibodies. Under his leadership Affitech AS was transformed through a reverse merger in 2009 with Pharmexa A/S a public Danish company and listed on the Copenhagen stock exchange. In 2010 he was one of the key resources concerning the implementation of a strategic partnership with the Russian Pharmaceutical IBC Generium as well as securing strategic investment from major Russian pharma players.
Prior to Affitech Martin was the Director of Technology at Axaron Bioscience AG responsible for transcription analysis and functional genomics. During that time he worked at Axaron’s parent company, LYNX Therapeutics Inc., Hayward, California, where he contributed to the process development of LYNX massive parallel cloning and sequencing technologies MegaClone, MegaSort and MPSS.
Martin Welschof did his post-doctoral training at the German Cancer Research Center's Department for Recombinant Antibody Technology and the University of Heidelberg's Department of Transplantation Immunology. He has a Ph.D. (Dr.rer.nat.) in the field of recombinant antibody technology from the University of Bielefeld, Germany.